A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis

https://doi.org/10.1016/S0149-2918(04)90035-5Get rights and content

Abstract

Background: Acute attacks of gouty arthritis are characterized by the rapid onset of severe pain, swelling, and erythema of the affected joint. Nonsteroidal anti-inflammatory drugs are considered the drugs of first choice for treating acute gout. Rofecoxib is a specific cyclooxygenase-2 inhibitor, which has demonstrated analgesic efficacy in the setting of acute pain. Whether it is effective in the treatment of acute gouty arthritis remains to be evaluated.

Objective: The aim of this study was to assess the efficacy and tolerability of rofecoxib compared with diclofenac sodium sustained release (SR) and meloxicam in the treatment of acute gouty arthritis.

Methods: In this single-blind, randomized, controlled, parallel-group study, patients aged ≥18 years with acute gout within 48 hours of onset were randomized to receive oral treatment with 2 tablets of rofecoxib (25 mg), diclofenac (75 mg), or meloxicam (7.5 mg) once daily for 7 days. The primary outcome measures were patients global assessment of response to therapy and investigator assessment of response to therapy on days 3 and 8. Other efficacy measurements included investigator assessment of total inflammatory scores on days 3 and 8 and patient assessment of pain intensity during the first 12 hours of treatment.

Results: Sixty-two patients (53 men, 9 women; mean [SD] age, 51.1 [12.1] years) were assigned to receive rofexocib (n = 20), diclofenac (n = 21), or meloxicam (n = 21). For patient global response to therapy on days 3 and 8, rofecoxib was associated with analgesic efficacy in significantly more patients compared with meloxicam (84.2% vs 40.0% of patients [P = 0.005] and 94.7% vs 60.0% of patients [P = 0.02], respectively); no significant differences versus diclofenac were found. Similarly, for investigator global assessment of response to therapy, a greater percentage of responders was found in the rofecoxib group compared with the meloxicam group on day 3 (88.9% vs 40.0% of patients [P = 0.02]), but the difference was not significant on day 8. A greater percentage of responders was found in the rofecoxib group compared with the diclofenac group on day 3 (88.9% vs 47.3% [P = 0.007]), but the difference was not significant on day 8. Compared with baseline, all regimens showed significant improvement in total inflammatory scores on days 3 and 8 (all P < 0.01). During the first 12 hours after dosing, pain intensity score was significantly reduced with rofecoxib starting at 0.5 hours (P < 0.05), but not with diclofenac or meloxicam. Clinical adverse events (AEs) were reported in 4 (20.0%), 7 (33.3%), and 6 (28.6%) patients in the rofecoxib, diclofenac, and meloxicam groups, respectively; the most common AEs reported were edema in 1 patient each in the rofecoxib (5.0%) and meloxicam (4.8%) groups and 2 patients (9.5%) in the diclofenac group and abdominal (1 [5.0%], 1 [4.8%], and 2 [9.5%], respectively). No significant differences in tolerability were found among the 3 treatment groups.

References (21)

There are more references available in the full text version of this article.

Cited by (56)

  • The efficacy of bloodletting therapy in patients with acute gouty arthritis: A systematic review and meta-analysis

    2022, Complementary Therapies in Clinical Practice
    Citation Excerpt :

    Manifesting episodically, it is caused by monosodium urate crystal depositions within and surrounding the joints [5]. AGA joint flares often include acute pain, joint swelling, warmth, erythema, and disabled motion [6–8]. Most patients experience metatarsophalangeal joint lesions while less common affected areas include knees, elbows, ankles, and wrists.

  • Diagnosis and treatment of shoulder disease in primary care

    2018, FMC Formacion Medica Continuada en Atencion Primaria
  • Traditional Chinese Medicine Formula “Xiaofeng granules” suppressed gouty arthritis animal models and inhibited the proteoglycan degradation on chondrocytes induced by monosodium urate

    2016, Journal of Ethnopharmacology
    Citation Excerpt :

    Namely, to ascertain the injury degree of articular cartilage, GAG and Hyp content regarded as the degradation indicators of proteoglycan and collagen can be examined. Patients often suffer the rapid onset of severe pain, swelling, warmth, erythema, and decreased range of motion in the affected joint during acute phase (Cheng et al., 2004; Neogi, 2011; So et al., 2010), leading to joint destruction when become chronic. Generally, effective treatment of acute gouty arthritis must target both the pain and the underlying inflammation.

  • Treatment of acute gout: A systematic review

    2014, Seminars in Arthritis and Rheumatism
    Citation Excerpt :

    One compared naproxen to prednisolone [21] and showed a similar decrease in pain with both treatments. Five studies [4,17–20] assessed the efficacy of COX-2 selective inhibitors for the treatment of acute gouty arthritis. Of these, 4 used indomethacin as a comparator all showing similar efficacy to indomethacin except low-dose celecoxib was statistically less effective than indomethacin [17–20].

  • Health-related quality of life and outcome measures in gout

    2012, Gout and Other Crystal Arthropathies
View all citing articles on Scopus
View full text